Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for Sorrento Therapeutics, Inc.
How SRNE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-12-31 | SP-102 (SEMDEXA™) | Phase 3 topline data readout | Phase 3 |
Readouts, endpoints and source filings for every SRNE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ji HenryDirector, Officer (See Remarks) | Buy | 88,888 4,765,805 held | $2.02 | 09/07/2022 |
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 1.37 M | 165.90 K |
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How SRNE ranks across every disease it competes in